Intarcia Therapeutics Stock | BioTech | Founded: 1997 | Funding to Date: $961,464,514

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

ENTERPRISE VALUE (based on primary fundings)

Learn more about a potential Intarcia Therapeutics IPO >>

Intarcia Therapeutics investors also invested in these private companies

Farallon Capital Management
Foresite Capital
Fred Alger Management
New Leaf Venture Partners
Intarcia Therapeutics went out of business on November 1, 2020. SharesPost no longer actively tracks this company.


Management Team
  • Kurt Graves - Chairman, President & Chief Executive Officer
  • Paul Feldman, Ph.D. - Head of Discovery and Translational Medicine
  • Fred Fiedorek, M.D. - Chief Medical Officer and Global Head of Regulatory Affairs
  • Raymond Keane - Chief Legal Officer
  • David Spellman - Chief Business Officer and Chief Financial Officer
  • Anders Vinther, Ph.D - Global Head of Technical Operations
  • Thane Wettig - Chief Commercial Officer
  • James Brady - Vice President, Human Resources
  • Thomas Alessi, Ph.D. - Vice President, Development and Manufacturing
  • Jay Smith - Chief Experience Officer
  • Andrew Young, M.B., Ch.B. (M.D.), Ph.D. - Chief Scientific Officer
Board Members
  • Kurt Graves -
  • Bryan Roberts, Ph.D. - Venrock
  • Gino Santini -
  • Nancy Thornberry -
  • Patrick Conway, MD -
  • Jim Rosenthal -
  • Jay S. Skyler, MD, MACP -
  • Bob Kerrey -

Other companies like Intarcia Therapeutics in the BioTech sector

Ginkgo Bioworks
Est. Val.: $4.89B
Human Longevity
Est. Val.: $50,396,793
Caribou Biosciences
Est. Val.: $143,800,000
Life Biosciences
Est. Val.: $500,000,000
American Gene Technologies International
Est. Val.: $265,000,000


Tokens Journal

The Diabetic Therapeutic Market  report  provides valuable and unique information which is very  essential. Further it also covers key players,application and future market condition.This information is extremely useful information for new and growing  company to mark themself over the market Diabetic Therapeutic market to grow at a CAGR OF 7.55% during the period 2017-2021. This …

Bitnews Today

Diabetic Therapeutic Market report evaluate the current opportunity and the future potential of the Diabetic Therapeutic market over the coming decade. Based on various parameters, Diabetic Therapeutic Market provides complete analysis of manufacturers, suppliers, distributors, traders, customers, major types and applications. “The global diabetic therapeutic market is growing at a high pace owing to the …